Team:Westminster

From 2012.igem.org

(Difference between revisions)
 
(51 intermediate revisions not shown)
Line 1: Line 1:
-
<!--- The Mission, Experiments --->
 
<html>
<html>
 +
<head>
<head>
-
<style type="text/css">
+
 
-
body {
+
<meta http-equiv="content-type" content="text/php; charset=utf-8" />
-
    background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff
+
 
-
}
+
<style type="text/css">
-
a {
+
@import url 'http://yui.yahooapis.com/2.9.0/build/reset/reset-min.css';
-
    color: #66c9c1;
+
ul {
-
}
+
list-style: none;
-
a:visited, td a:visited {
+
}
-
    background: #ffeebb !important;
+
body {
-
}  
+
font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;  
-
table, p {
+
font-weight: 300;
-
    font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif;  
+
/* background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff;*/
-
    font-weight: 300;
+
background-color:#FFF;
-
    font-size: 11pt;
+
color: #666666;
-
    color: #666666;
+
-
}
+
}
-
div#globalWrapper > div {
+
h1 {
-
    box-shadow: 0 0 17px -4px #666666;
+
color: #ff0000;
-
}
+
font-size: 18pt;
-
div#content {
+
margin-bottom: 0.5em;
-
    width: 945px;
+
}
-
    padding: 10px;
+
p {
-
}
+
 
-
ul#navigation {
+
}
-
    list-style: none;
+
a {
-
    overflow: auto;
+
-
}
+
}
-
ul#navigation > li {
+
#p-logo {
-
    background: url("http://www.westminsterigem.com/files/theme/nav-sep.png") no-repeat scroll right 10px transparent;
+
background: #444444;
-
    float: left;
+
}
-
    height: 25px;
+
div#top-section,
-
    padding: 0px 15px;
+
div#content {
-
}
+
box-shadow: 0px 0px 17px -4px #666666;
-
ul#navigation > li.first-item {
+
padding:0px;
-
    padding-left: 0px;
+
margin-top:0px;
-
}
+
 
-
ul#navigation > li.last-item {
+
}
-
    background: none;
+
div#wrapper {
-
    padding-right: 0px;
+
position: relative;
-
}
+
width: 100%;
-
ul#navigation a.navlink {
+
font-size: 12pt;
-
    line-height: 25px;
+
margin: 0 auto;
-
    list-style: none outside none;
+
background: #ffffff;
-
    color: #545454;
+
background-attachment: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png');
-
    border-top: 3px solid transparent;
+
background-repeat: no-repeat;
-
    padding: 3px 15px;
+
-
}
+
padding:0px;
-
ul#navigation a.navlink:hover {
+
margin-top:0px;
-
    border-top: 3px solid #66c9c1;
+
top:0px;
-
    color: #545454;
+
-
    text-decoration: none;
+
}
-
}
+
div#header {
-
div#footer-box {
+
height: 120px;
-
    border-radius: 0 0 5px 5px;
+
width: 100%;
-
}
+
background-color:#000;
-
</style>
+
background: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png');
 +
background-repeat: no-repeat;
 +
z-index:10;
 +
position:relative;
 +
top:0px;
 +
left:0px;
 +
}
 +
div#header div#logo {
 +
position: relative;
 +
width: 260px;
 +
right:10px;
 +
top:-9px;
 +
float:right;
 +
 
 +
margin-bottom: 0px;
 +
/*
 +
height: 0px;
 +
margin: 0 auto;*/
 +
}
 +
div#header div#logo a {
 +
float:left;
 +
display:block;
 +
margin-left:10px;
 +
 
 +
}
 +
 
 +
 +
div#navigation {
 +
width: 850px;
 +
height: 27px;
 +
background:rgba(0,0,0,.5);
 +
float:left;
 +
position:relative;
 +
top:54px;
 +
}
 +
ul#navigation-list {
 +
height: 27px;
 +
line-height: 27px;
 +
overflow: auto;
 +
}
 +
ul#navigation-list > li {
 +
float: left;
 +
margin-top:-5px;
 +
}
 +
ul#navigation-list > li > ul {
 +
position: absolute;
 +
display: none;
 +
background: #000000;
 +
z-index: 100000;
 +
}
 +
ul#navigation-list > li > ul.submenu {
 +
margin: 0;
 +
}
 +
ul#navigation-list > li > ul.submenu li {
 +
padding: 2px 0px;
 +
}
 +
ul#navigation-list a.navlink {
 +
color: #ffffff;
 +
font-weight: normal;
 +
display: block;
 +
padding: 0px 10px;
 +
text-decoration: none;
 +
}
 +
ul#navigation-list a.navlink.active,
 +
ul#navigation-list a.navlink:hover {
 +
color: #ff0000;
 +
}
 +
div#home-main-image {
 +
text-align: center;
 +
background-color: #410000;
 +
height:475px;
 +
border-bottom:1px #000 solid;
 +
}
 +
div#the-content {
 +
position:relative;
 +
top:-19px;
 +
 +
}
 +
div#home-main-image img {
 +
/*width: 885px;
 +
height: 300px;
 +
margin-bottom: 20px;
 +
border-radius: 20px;
 +
*/
 +
}
 +
div.text-box {
 +
background: #444444;
 +
color: #ffffff;
 +
padding: 15px 20px;
 +
border-radius: 10px;
 +
 +
}
 +
div#footer-box {
 +
border-radius: 0 0 5px 5px;
 +
}
 +
#bodyContent {
 +
}
 +
#three-column
 +
{
 +
margin:0 auto;
 +
width:850px;
 +
margin-top:50px;
 +
 +
}
 +
 +
.col
 +
{
 +
text-align:justify; float:left; margin:5px;
 +
}
 +
.col h1
 +
{
 +
font-size:14px;
 +
color:#000;
 +
 +
}
 +
/* hide native rubbish*/
 +
#top-section {display:none; position:absolute; left:0px; top:-200px;}
 +
#top-section a { color:#FFF; }
 +
.firstHeading {display:none; position:absolute; left:0px; top:-200px;}
 +
.annoying-gap {
 +
padding:0px;
 +
margin:0px;
 +
line-height:0;
 +
}
 +
 +
#contentSub, #siteSub {display:none;}
 +
 +
#control-btn
 +
{
 +
 +
width: 20px;
 +
height: 20px;
 +
position:absolute;
 +
top:0px;
 +
left:5px;
 +
 +
line-height: 0px;
 +
 +
 +
}
 +
.btn-cog {
 +
background: url('https://static.igem.org/mediawiki/2012/d/d4/Control-panel-sml.png') #000 no-repeat  2px 2px;
 +
}
 +
.btn-close {
 +
background: url('https://static.igem.org/mediawiki/2012/d/d0/Close-btn.png')  #000 no-repeat  2px 2px;
 +
}
 +
.right-menu li a, .left-menu li a {background: none}
 +
</style>
 +
 
 +
<script type="text/javascript" src="http://code.jquery.com/jquery-1.8.2.min.js"></script>
 +
<script type="text/javascript">
 +
$('document').ready(function() {
 +
 +
// menu
 +
$('li.submenu-holder').hover(function() {
 +
$(this).children('ul.submenu').stop(true).fadeIn('fast');
 +
}, function() {
 +
$(this).children('ul.submenu').stop(true).fadeOut('fast');
 +
});
 +
 
 +
              // hide standard team basics
 +
              $('#top-section').hide();
 +
  $('#bodyContent p:first').addClass("annoying-gap");
 +
 
 +
 +
$('#control-btn').click( function(){
 +
 +
if ($('#control-btn').hasClass("btn-cog"))
 +
{
 +
showTopMenu();
 +
$('#control-btn').animate({left: "-20px"});
 +
$('#control-btn').addClass("btn-close");
 +
$('#control-btn').removeClass("btn-cog");
 +
} else
 +
{
 +
hideTopMenu();
 +
$('#control-btn').animate({left: "0px"});
 +
$('#control-btn').addClass("btn-cog");
 +
$('#control-btn').removeClass("btn-close");
 +
}
 +
});
 +
 +
});
 +
 +
 +
 +
 +
var $bar;
 +
function hideTopMenu()
 +
{
 +
$bar.slideUp('fast');
 +
 +
}
 +
function showTopMenu()
 +
{
 +
if ($bar==null)
 +
{
 +
$bar = $("#top-section").clone();
 +
$($bar.find("#search-controls")).remove();
 +
$($bar.find("#p-logo")).remove();
 +
$("#wrapper").prepend($bar);
 +
$bar.css("position", "absolute");
 +
$bar.css("top", "0px");
 +
$bar.css("left", "0px");
 +
$bar.css("background", "none");
 +
$bar.css("background", "rgba(0,0,0,.5)");
 +
$bar.css("height", "20px");
 +
$bar.css("border", "none");
 +
$bar.css("z-index", "100");
 +
$bar.css("color", "#000");
 +
 +
 +
}
 +
$bar.slideDown('fast');
 +
 +
$('#control-btn').mouseover( function(){
 +
 +
});
 +
}
 +
</script>
</head>
</head>
<body>
<body>
-
<ul id="navigation">
+
<div id="wrapper">
-
  <li class="first-item"><a href="https://2012.igem.org/Team:Westminster" class="navlink">Home</a></li>
+
 
-
  <li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li>
+
<div id="header">
-
  <li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li>
+
  <div id="control-btn" class="btn-cog"></div>
-
  <li><a href="https://2012.igem.org/Team:Westminster/Project"class="navlink">Project</a></li>
+
 
-
  <li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li>
+
<div id="navigation">
-
  <li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li>
+
<ul id="navigation-list">
-
  <li><a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a></li>
+
<li><a href="https://2012.igem.org/Team:Westminster" class="navlink active">Home</a></li>
-
  <li><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
+
<li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li>
-
  <li class="last-item"><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li>
+
<li class="submenu-holder">
-
</ul>
+
<a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Project</a>
-
<div class="wrap">
+
 
-
<img src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" style="float: left; border: 0; margin: 7px;">
+
<ul class="submenu">
-
<p class="content">
+
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Overview</a></li>
-
We have created a genetically engineered machine to identify, isolate and eliminate Cancer Stem Cells (CSCs). According to the latest Cancer Stem Cell Theory, not all the cancer cells have the same ability to generate new tumors. Tumor growth is mostly driven by a small proportion of cells, the CSCs. In addition to having high proliferation rates, CSCs are more resistant to chemotherapy. This indicates that while regular cancer cells are killed, CSCs may remain unaffected and give rise to new tumors once the treatment stops. CSCs produce increased levels of a particular enzyme, Aldehyde Dehydrogenase.</p>
+
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Problem"class="navlink">The Problem</a></li>
-
<p class="content">We have identified its 3 most frequent isoforms (ALDH1A1, ALDH1A3 and ALDH3A1) in aggressive types of cancer, and used their gene promoters to build our CSC-targeting constructs: the iSTEM -Intelligent Synthetic Tumor Eliminating Machine.</p>
+
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Experiments"class="navlink">Experiments</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Protocols"class="navlink">Protocols</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Results"class="navlink">Results</a></li>
 +
 
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li>
 +
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li>
 +
                           
 +
                 
 +
</ul>
 +
</li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li>
 +
<li><a href="https://2012.igem.org/Team:Westminster/Outreach"class="navlink">Outreach</a></li>
 +
                    <li><a href="https://2012.igem.org/Team:Westminster/Judging"class="navlink">Judging Criteria</a></li>
 +
 
 +
 +
<li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li>
 +
</ul><!-- #navigation-list -->
 +
</div><!-- #navigation -->
 +
            <div id="logo">
 +
                    <a href="http://www.igem.org" title="iGEM homepage"><img src="https://static.igem.org/mediawiki/igem.org/d/dc/Igem-small-white.png" alt="iGEM logo" width="55" height="44" /></a>
 +
<a href="https://2012.igem.org/Team:Westminster">
 +
<img src="https://static.igem.org/mediawiki/2012/a/ae/Logo-white.png" alt="iSTEM - intelligent synthetic tumour eliminating machine" width="172" height="66" title="iSTEM - intelligent synthetic tumour eliminating machine" />
 +
</a>
 +
</div><!-- #logo -->
 +
</div><!-- #header -->
 +
 
 +
<div id="the-content">
 +
<div id="home-main-image">
 +
<!--img src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" alt="Welcome" title="Welcome to our home!" /--->
 +
      <div style="float:left;padding-left:30px;padding-top:50px; width:380px">
 +
            <h1 style="text-align:left;border:none; color:#fff; position:relative;bottom:0px; left:0px; margin:0px; padding:0px 0px 20px 0px;">Fighting cancer from the inside out</h1>
 +
<div style="color:white; text-align:justify;">Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.<br/><br/>
 +
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.</div>
 +
 
 +
 
 +
</div>
 +
<div  style="float:left; width:500px; padding-left:50px; padding-top:150px; text-align:center">
 +
<img src="https://static.igem.org/mediawiki/2012/8/8a/Tumor.png" alt="Tumor" width="218" height="179" />
</div>
</div>
-
<script type="text/javascript" src="http://tabletpc.redbluesquare.co.uk/fancydropdown.js"></script>
+
</div><!-- #home-main-image -->
 +
 +
 +
           
 +
  <div id="three-column">
 +
 
 +
  <div class="col">
 +
    <img src="https://static.igem.org/mediawiki/igem.org/d/d7/IntegratedDNALogo.jpg" width="146" height="61"/>
 +
    </div>
 +
    <div class="col">
 +
    <img src="https://static.igem.org/mediawiki/igem.org/b/b9/GeneiousLogo.jpg" width="136" height="54"/>
 +
    </div>
 +
    <div class="col">
 +
    <img src="https://static.igem.org/mediawiki/igem.org/a/af/MathWorksLogo.jpg" width="202" height="40"/>
 +
    </div>
 +
    <div class="col">
 +
    <img src="https://static.igem.org/mediawiki/igem.org/8/8e/AutodeskLogo.jpg" width="161" height="41"/>
 +
    </div>
 +
    <div class="col">
 +
    <img src="https://static.igem.org/mediawiki/igem.org/c/c7/UniversityWestminsterLogo.jpg"/>
 +
    </div>
 +
   
 +
  </div>
 +
 
 +
</div><!-- #the-content -->
 +
 
 +
</div><!-- #wrapper -->
 +
 
 +
 
</body>
</body>
-
</html>
 
-
{|align="justify"
+
</html>
-
|You can write a [[background|wiki]] [[of your team]] here.  Give us a background of your team, the members, etc.  Or tell us more about something of your choosing.
+
[[iGEM 2013]]
-
|[[Image:Westminster_logo.png|200px|right|frame]]
+
-
|-
+
-
|
+
-
''We have created a genetically engineered machine to identify, isolate and eliminate Cancer Stem Cells (CSCs). According to the latest Cancer Stem Cell Theory, not all the cancer cells have the same ability to generate new tumors. Tumor growth is mostly driven by a small proportion of cells, the CSCs. In addition to having high proliferation rates, CSCs are more resistant to chemotherapy. This indicates that while regular cancer cells are killed, CSCs may remain unaffected and give rise to new tumors once the treatment stops. CSCs produce increased levels of a particular enzyme, Aldehyde Dehydrogenase. We have identified its 3 most frequent isoforms (ALDH1A1, ALDH1A3 and ALDH3A1)in aggressive types of cancer, and used their gene promoters to build our CSC-targeting constructs: the iSTEM -Intelligent Synthetic Tumor Eliminating Machine.  ''
+
-
|[[Image:Westminster_team.png|right|frame|The team]]
+
-
|-
+
-
|
+
-
|align="center"|[[Team:Westminster | Team Westminster]]
+
-
|}
+

Latest revision as of 18:58, 9 August 2013

Fighting cancer from the inside out

Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.

The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.
Tumor

iGEM 2013